Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IONIS FB LRx

X
Drug Profile

IONIS FB LRx

Alternative Names: RO-7434656; ASO Factor B; IONIS-FB-LRx; IONIS-FB-LRX; ISIS-696844; RG-6299

Latest Information Update: 09 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Ionis Pharmaceuticals; Roche
  • Class Antisense oligonucleotides; Eye disorder therapies
  • Mechanism of Action Complement factor B expression inhibitors; Gene silencing
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III IgA nephropathy
  • Phase II Age-related macular degeneration

Most Recent Events

  • 09 May 2024 Roche plans to file regulatory filing for IgA nephropathy, in or after 2027 (Roche pipeline, May 2024)
  • 09 May 2024 Roche plans to submit regulatory fillings in Age-related macular degeneration in 2027 or beyond (Roche pipeline, May 2024)
  • 11 Apr 2024 Ionis Pharmaceuticals completes a phase-II trial in IgA nephropathy (In adults, In the elderly) in Singapore, Australia, Canada and New Zealand (SC) (NCT04014335)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top